Samsung Biologics Co.,Ltd.

KSE 207940.KS

Samsung Biologics Co.,Ltd. Receivables for the year ending December 31, 2023: USD 0.00

Samsung Biologics Co.,Ltd. Receivables is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Samsung Biologics Co.,Ltd. Receivables for the year ending December 31, 2022 was USD 647.92 M, a 79.92% change year over year.
Samsung Biologics Co.,Ltd. Receivables for the year ending December 31, 2021 was USD 360.11 M, a 0.00% change year over year.
Samsung Biologics Co.,Ltd. Receivables for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Samsung Biologics Co.,Ltd. Receivables for the year ending December 31, 2019 was USD 0.00, a -100.00% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

KSE: 207940.KS

Samsung Biologics Co.,Ltd.

CEO	Mr. John Chongbo Rim
IPO Date	Nov. 11, 2016
Location	South Korea
Headquarters	300, Songdo Bio-daero
Employees	4,523
Sector	Healthcare
Industries Biotechnology 3D Printing Containers & Packaging Frozen Foods Glass Personal Care Pharmaceuticals Plastics

Description

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Key trends

Past 5 years